Biostem Technologies (NASDAQ:BSEM) Stock Falls 5.4% – What’s Next?

Biostem Technologies, Inc. (NASDAQ:BSEM)’s stock price traded down 5.4% during trading on Friday. The company traded as low as $1.57 and last traded at $1.57. Approximately 133,912 shares were traded during trading, a decline of 8% from the average daily volume of 146,193 shares. The stock had previously closed at $1.66.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Wall Street Zen raised shares of Biostem Technologies to a “sell” rating in a report on Saturday, September 5th. Weiss Ratings initiated coverage on Biostem Technologies in a research note on Wednesday, August 19th. They issued a “sell (d-)” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $9.00.

Biostem Technologies Price Performance

The stock has a market capitalization of $29.31 million, a PE ratio of -0.98 and a beta of 0.17. The company has a 50 day moving average price of $3.28 and a 200-day moving average price of $4.12.

Biostem Technologies (NASDAQ:BSEM) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.02). The business had revenue of $7.90 million during the quarter, compared to analysts’ expectations of $6.35 million. Biostem Technologies had a negative return on equity of 60.22% and a negative net margin of 76.02%. As a group, equities analysts anticipate that Biostem Technologies, Inc. will post -1.90 earnings per share for the current year.

About Biostem Technologies

BioStem Technologies, Inc is a biotechnology company focused on regenerative medicine and biologic tissue products. The company develops, manufactures and commercializes human tissue allografts intended to support wound care, tissue repair and other medical applications.

Its product portfolio includes placental- and birth-tissue-derived products, such as amniotic membrane and umbilical cord allografts. These products are marketed for use by healthcare providers in areas including wound management, surgical procedures and related regenerative-care applications.

BioStem Technologies serves the U.S.